Evonik Launches Care Product Lines Designed Specifically For Medical Market
Polymer’s Biocompatibility, Chemical Resistance Excellent For Medical Devices
Evonik Corporation launched VESTAMID® Care, TROGAMID® Care and VESTAKEEP® Care product lines of high-performance polymers, which are designed specifically for use in medical devices.
The properties of VESTAMID® Care, TROGAMID® Care and VESTAKEEP® Care polymers include high elasticity, impact and chemical resistance, and durability, making them excellent materials for medical devices including catheters, surgical instruments and hearing aids.
“Evonik works closely with its customers to develop materials which meet application requirements and market needs,” said Jeff Smith, vice president and general manager of Evonik’s High Performance Polymers business line. “Evonik is one of the leaders in polymer design technology and assists its customers throughout the product development process. We created these product lines to help our customers’ meet their medical device manufacturing needs.”
Care products are biocompatible and are customized depending on the technical requirements of the medical device based on characteristics such as either flexible or rigid, and either transparent or translucent.
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america. Please visit us on Facebook at www.facebook.com/EvonikNorthAmerica. Follow us on Twitter at http://twitter.com/EvonikN_America.
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.